Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Key to changes
?
Text removedfrom 2019 Q1- Text added to 2019 Q2
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. sophomore Avg
|
Content analysis
?Positive | |
Negative | |
Uncertain | |
Constraining | |
Legalese | |
Litigous | |
Readability |
H.S. junior Avg
|
New words:
Antitrust, appointed, April, Chairman, DMD, Dr, duchenne, dystrophy, elexacaftor, guide, HSR, Jeffrey, Kewalramani, Kymera, Leiden, muscular, myotonic, neuromuscular, pharmacokinetic, preceding, President, proprietary, Reshma, RNA, Rodino, role, strong, submission, therapy, waiting
Removed:
account, accrual, acid, ataxia, channel, commence, commercialize, commercially, Concert, converted, convertible, distinct, earned, ENaC, epithelial, hand, inhibitor, initiation, kinase, messenger, modification, mRNA, Parion, promissory, pulmonary, remained, ribonucleic, seeking, sodium, targeting, telangiectasia, unrelated
Valuein 2019 Q1 filing- Value in 2019 Q2 filing
Original filings
Filing view